Intellia Therapeutics (NASDAQ:NTLA) Earns Buy Rating from Chardan Capital

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “buy” rating reaffirmed by equities research analysts at Chardan Capital in a note issued to investors on Friday,Benzinga reports. They currently have a $26.00 price target on the stock. Chardan Capital’s price target points to a potential upside of 88.68% from the company’s current price.

Several other research firms also recently weighed in on NTLA. Wall Street Zen lowered shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, January 18th. Barclays dropped their price target on Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday, November 7th. Wells Fargo & Company decreased their price objective on Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating for the company in a report on Friday, November 7th. Evercore set a $8.00 target price on Intellia Therapeutics and gave the stock an “in-line” rating in a report on Tuesday, November 11th. Finally, Royal Bank Of Canada dropped their price target on shares of Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Friday, November 7th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $17.90.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $13.78 on Friday. The company has a market capitalization of $1.60 billion, a PE ratio of -3.60 and a beta of 2.10. Intellia Therapeutics has a fifty-two week low of $5.90 and a fifty-two week high of $28.25. The company has a 50 day simple moving average of $11.89 and a two-hundred day simple moving average of $13.03.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.16. The firm had revenue of $23.02 million during the quarter, compared to analyst estimates of $12.17 million. Intellia Therapeutics had a negative return on equity of 55.36% and a negative net margin of 609.85%.The business’s quarterly revenue was up 78.4% on a year-over-year basis. During the same period last year, the company posted ($1.27) EPS. Research analysts predict that Intellia Therapeutics will post -5.07 EPS for the current year.

Insider Activity at Intellia Therapeutics

In related news, EVP James Basta sold 10,397 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $95,756.37. Following the completion of the transaction, the executive vice president owned 101,528 shares of the company’s stock, valued at approximately $935,072.88. The trade was a 9.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the transaction, the executive vice president directly owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. The trade was a 7.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 53,051 shares of company stock worth $488,600. 3.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in NTLA. Caitong International Asset Management Co. Ltd bought a new position in Intellia Therapeutics in the 3rd quarter worth about $30,000. Blue Bell Private Wealth Management LLC purchased a new position in Intellia Therapeutics in the 3rd quarter worth approximately $30,000. Advisory Services Network LLC purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at $33,000. Headlands Technologies LLC purchased a new position in Intellia Therapeutics in the second quarter worth $26,000. Finally, Comerica Bank increased its stake in Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after acquiring an additional 901 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Key Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations: Intellia reported a smaller-than-expected loss (‑$0.83 vs. consensus ‑$0.99) and revenue of $23.0M (well above estimates), which investors view as proof of commercial progress and operational execution. Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
• Positive Sentiment: Pipeline and regulatory progress: FDA lifted the clinical hold on MAGNITUDE‑2 (nex‑z) and management outlined 2026 launch plans for lonvo‑z (HAE) with mid‑2026 Phase 3 readout expectations and a potential BLA in H2 2026 — milestones that materially de‑risk commercial timelines if achieved. Intellia outlines 2026 lonvo-z launch plans as FDA lifts clinical hold on MAGNITUDE-2
• Positive Sentiment: Strong cash runway: Intellia ended 2025 with roughly $605M in cash, cash equivalents and marketable securities — a balance that supports continued clinical development and commercial preparation into the near‑term. Intellia Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
• Positive Sentiment: Analyst support: Chardan Capital reaffirmed a “buy” and set a $26 price target, signaling notable upside from current levels and providing dealer/retail validation for the bull case. Benzinga
• Neutral Sentiment: Broker estimates: Brookline Capital published a slate of near‑term quarterly EPS forecasts (all negative) but raised long‑range FY2028/FY2029 EPS projections, reflecting high uncertainty today but improved long‑term expectations if pipeline succeeds. MarketBeat Q4 coverage / analyst notes
• Neutral Sentiment: Earnings call detail: Management emphasized commercial readiness for lonvo‑z and clinical plans for nex‑z; transcripts and call highlights are available for deeper review. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Profitability and consensus outlook remain weak: the company still posts large negative margins and the consensus full‑year EPS forecast is deeply negative, keeping NTLA a high‑volatility, binary biotech bet until clinical/commercial milestones are met. MarketBeat: Q4 results and metrics
• Negative Sentiment: Market reaction: despite the positive operational news, the shares are trading lower today — likely reflecting profit‑taking, macro/sector pressure on biotech, and investor caution about execution risk and near‑term losses.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.